This content is machine translated ESMO 2017 in Madrid Blocking the “escape route” for the tumor Upsets in first-line therapy of non-small cell EGFR-mutated lung cancer are imminent. With the FLAURA trial, osimertinib is confidently presenting itself for the first time as a treatment option for…
View Post 4 min This content is machine translated News from dermatooncology Melanoma with or without BRAF mutation – new therapies in the pipeline Data from two phase III trials (both from the research group led by Caroline Robert, MD, Institut Gustave Roussy in Villejuif, Paris) published earlier this year highlight the rapid development…
View Post 5 min This content is machine translated Interdisciplinary care for skin cancer patients New drugs for the clinician What’s new in skin cancer therapy? An educational session at UniversitySpital Zurich focused on the options available to patients from improved immunotherapy and targeted treatments with BRAF and MEK inhibitors…
